Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn HT-B
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn TDM-105795
Research
5 / 1000+ results
research Transcriptome profiling of whisker follicles in methamphetamine self-administered rats
Methamphetamine affects gene expression in rat whisker follicles, with key genes linked to addiction.
research Molecular Mechanism of Avicennia marina (Forssk.) Vierh. in Inhibiting Hepatitis C Virus Based on Network Pharmacology and Molecular Docking
Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
research Genome-Wide Association Studies for Immunoglobulin Concentrations in Colostrum and Serum in Chinese Holstein
Certain genes influence immunoglobulin levels in Chinese Holstein cows, which can improve calf health.
research Genome-Wide Association Studies for Immunoglobulins in Colostrum and Serum in Chinese Holstein
Selective breeding can enhance immunity in dairy cattle.
research Calreticulin: non‐endoplasmic reticulum functions in physiology and disease
Calreticulin has roles in healing, immune response, and disease beyond its known functions in the endoplasmic reticulum.
Community Join
5 / 1000+ resultscommunity (Topical) Quercetin might be a good add on to the hair loss stack
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
community Isn't it kind of strange that hair loss happens at where the 2 main superficial temporal arterty branches (temples and crown) are?
Hair loss may be linked to blood flow and inflammation, with treatments like Minoxidil, finasteride, and quercetin being discussed. The conversation also mentions the role of 5AR enzyme distribution in hair follicles.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community Hope Medicine's HMI-115 could be out in 2027 per Company Founder
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.